Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
about
Therapeutic options for management of endometrial hyperplasiaIdentification of polyproline II regions derived from the proline-rich nuclear receptor coactivators PNRC and PNRC2: new insights for ERα coactivator interactions.A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancerA Chip for Estrogen Receptor Action: Detection of Biomarkers Released by MCF-7 Cells through Estrogenic and Anti-Estrogenic Effects.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxelPrediction of the endocrine disruption profile of pesticides.Precision oncology: neither a silver bullet nor a dream.Effect of dioxin and 17β-estradiol on the expression of cytochrome P450 1A1 gene via an estrogen receptor dependent pathway in cellular and xenografted models.Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
P2860
Q26783569-386387CB-EF70-4211-B7F6-96310FCF92A6Q30009591-D2A2248C-A06E-4C13-8623-7B73B0FBEBA2Q35596991-BE2FE17B-C308-4FAD-9823-B0D945361C04Q36432567-8A311D60-7E03-4E07-8191-0CC0EDC29C35Q37137065-8D73BB3F-C2F6-4EBE-8E44-1A5A0065F27EQ38695994-8A592A26-C90A-41CF-9278-304CA0C03FF2Q41140406-C13976E7-0AED-4EB8-A704-E62D36865597Q46642235-CE7839A4-7C06-441C-A2D3-52EC99166025Q47737073-D9889E44-B0D5-41B3-9937-0A2B4521753AQ50943071-CC597481-A331-4572-9C61-835D3FBBCEE2Q52769257-EDFA8A0D-8F9A-4960-A242-8880722CA7CAQ54349937-4C6BFDBD-9BA0-4F19-B959-C7A7CA78972A
P2860
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Emerging data on the efficacy ...... py for advanced breast cancer.
@ast
Emerging data on the efficacy ...... py for advanced breast cancer.
@en
type
label
Emerging data on the efficacy ...... py for advanced breast cancer.
@ast
Emerging data on the efficacy ...... py for advanced breast cancer.
@en
prefLabel
Emerging data on the efficacy ...... py for advanced breast cancer.
@ast
Emerging data on the efficacy ...... py for advanced breast cancer.
@en
P2860
P1476
Emerging data on the efficacy ...... py for advanced breast cancer.
@en
P2093
Sarah M Scott
Steven E Come
P2860
P304
P356
10.1517/14740338.2011.595560
P407
P50
P577
2011-06-24T00:00:00Z